港股異動丨友邦保險拉昇升超2%,Q3新業務價值升35%為歷年同期最高
友邦保險(1299.HK)盤初拉昇一度升2.49%至70港元,股價創10月18日以來新高。公司今早公佈業績顯示,第三季,新業務價值9.94億美元;按固定及實質匯率計同比分別升35%及34%,年化新保費19.38億美元,按固定及實質匯率計分別升54%及52%,新業務價值利潤率51.2%,分別降7及6.9個百分點。友邦保險集團首席執行官兼總裁李源祥表示,集團錄得歷來最高的第三季新業務價值。集團延續上半年非常強勁的表現,作為主要增長引擎的中國內地、中國香港、東盟和印度業務,均進一步實現雙位數字增長,推動集團整體新業務價值上升35%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.